gene

Leading Academic and Manufacturing Organizations Join Ori Biotechs Preferred Partner Network to Accelerate the Commercialization of Cell and Gene TherapiesLeading Academic and Manufacturing Organizations Join Ori Biotechs Preferred Partner Network to Accelerate the Commercialization of Cell and Gene Therapies

Leading Academic and Manufacturing Organizations Join Ori Biotechs Preferred Partner Network to Accelerate the Commercialization of Cell and Gene Therapies

Preferred Partner Network (PPN) members will become Centers of Excellence for the IRO® platform combining best-in-class technology with industry-leading development…

2 weeks ago
NewBiologix Announces White Paper on Improving the Manufacturing of Recombinant Adeno-Associated Viruses for Use in Cell & Gene TherapiesNewBiologix Announces White Paper on Improving the Manufacturing of Recombinant Adeno-Associated Viruses for Use in Cell & Gene Therapies

NewBiologix Announces White Paper on Improving the Manufacturing of Recombinant Adeno-Associated Viruses for Use in Cell & Gene Therapies

March 05, 2025 03:00 ET  | Source: NewBiologix LAUSANNE, Switzerland, March 05, 2025 (GLOBE NEWSWIRE) -- NewBiologix, a technology innovation…

1 month ago
CrisprBits opens Research and Innovation Centre for CRISPR Gene Editing and Diagnostics in BengaluruCrisprBits opens Research and Innovation Centre for CRISPR Gene Editing and Diagnostics in Bengaluru

CrisprBits opens Research and Innovation Centre for CRISPR Gene Editing and Diagnostics in Bengaluru

BENGALURU, India, Jan. 16, 2025 /PRNewswire/ -- Bengaluru-based biotechnology startup, CrisprBits Private Limited, has inaugurated a CRISPR gene editing and…

3 months ago
CrisprBits opens Research and Innovation Centre for CRISPR Gene Editing and Diagnostics in BengaluruCrisprBits opens Research and Innovation Centre for CRISPR Gene Editing and Diagnostics in Bengaluru

CrisprBits opens Research and Innovation Centre for CRISPR Gene Editing and Diagnostics in Bengaluru

BENGALURU, India, Jan. 16, 2025 /PRNewswire/ -- Bengaluru-based biotechnology startup, CrisprBits Private Limited, has inaugurated a CRISPR gene editing and…

3 months ago
Voyager Selects Tau Silencing Gene Therapy Development Candidate for Alzheimers DiseaseVoyager Selects Tau Silencing Gene Therapy Development Candidate for Alzheimers Disease

Voyager Selects Tau Silencing Gene Therapy Development Candidate for Alzheimers Disease

November 20, 2024 07:00 ET | Source: Voyager Therapeutics, Inc. - Candidate VY1706 demonstrates significant reductions of tau at low…

5 months ago
Intellia Announces First Clinical Evidence from Ongoing Phase 1 Study that Nexiguran Ziclumeran (nex-z), an In Vivo CRISPR/Cas9-Based Gene Editing Therapy, May Favorably Impact Disease Progression inTransthyretin (ATTR) AmyloidosisIntellia Announces First Clinical Evidence from Ongoing Phase 1 Study that Nexiguran Ziclumeran (nex-z), an In Vivo CRISPR/Cas9-Based Gene Editing Therapy, May Favorably Impact Disease Progression inTransthyretin (ATTR) Amyloidosis

Intellia Announces First Clinical Evidence from Ongoing Phase 1 Study that Nexiguran Ziclumeran (nex-z), an In Vivo CRISPR/Cas9-Based Gene Editing Therapy, May Favorably Impact Disease Progression inTransthyretin (ATTR) Amyloidosis

Consistently rapid, deep and durable reduction in serum TTR accompanied by evidence of disease stabilization or improvement after a one-time…

5 months ago
Intellia Announces First Clinical Evidence from Ongoing Phase 1 Study that Nexiguran Ziclumeran (nex-z), an In Vivo CRISPR/Cas9-Based Gene Editing Therapy, May Favorably Impact Disease Progression inTransthyretin (ATTR) AmyloidosisIntellia Announces First Clinical Evidence from Ongoing Phase 1 Study that Nexiguran Ziclumeran (nex-z), an In Vivo CRISPR/Cas9-Based Gene Editing Therapy, May Favorably Impact Disease Progression inTransthyretin (ATTR) Amyloidosis

Intellia Announces First Clinical Evidence from Ongoing Phase 1 Study that Nexiguran Ziclumeran (nex-z), an In Vivo CRISPR/Cas9-Based Gene Editing Therapy, May Favorably Impact Disease Progression inTransthyretin (ATTR) Amyloidosis

Consistently rapid, deep and durable reduction in serum TTR accompanied by evidence of disease stabilization or improvement after a one-time…

5 months ago
AlveoGene Receives Rare Pediatric Disease Designation (RPDD)from FDA for AVG-002, its Novel, Inhaled Gene Therapy forLethal Neonatal Surfactant Protein B (SP-B) DeficiencyAlveoGene Receives Rare Pediatric Disease Designation (RPDD)from FDA for AVG-002, its Novel, Inhaled Gene Therapy forLethal Neonatal Surfactant Protein B (SP-B) Deficiency

AlveoGene Receives Rare Pediatric Disease Designation (RPDD)from FDA for AVG-002, its Novel, Inhaled Gene Therapy forLethal Neonatal Surfactant Protein B (SP-B) Deficiency

Inherited SP-B deficiency is an ultra-rare monogenic cause of fatal respiratory distress syndrome in newborn infantsClinical estimates for SP-B deficiency…

5 months ago
Ring Therapeutics Announces New Strategic Partnerships with A*STAR and SERI to Establish Gene Therapy R&D Efforts in Singapore, a Growing Global Biotech HubRing Therapeutics Announces New Strategic Partnerships with A*STAR and SERI to Establish Gene Therapy R&D Efforts in Singapore, a Growing Global Biotech Hub

Ring Therapeutics Announces New Strategic Partnerships with A*STAR and SERI to Establish Gene Therapy R&D Efforts in Singapore, a Growing Global Biotech Hub

CAMBRIDGE, Mass., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Ring Therapeutics, a life sciences company founded by Flagship Pioneering to revolutionize…

5 months ago